Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
10:53am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals announced positive results for a major clinical trial and shares are up more than 200% because of it.
Madrigal Pharmaceuticals shares soar on positive trial results for its NASH and liver fibrosis drug resmetirom
10:41am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares have soared more than 250% after the biopharmaceutical company shared positive topline results from its pivotal Phase 3 MAESTRO-NASH biopsy clinical t
Why Is Madrigal Pharmaceuticals (MDGL) Stock Up 216% Today?
09:48am, Monday, 19'th Dec 2022
Madrigal Pharmaceuticals (NASDAQ: MDGL ) stock is rocketing higher on Monday after sharing results from its novel therapeutics for nonalcoholic steatohepatitis (NASH) treatment. The company reported p
Madrigal Pharma Stock Triples After Knocking NASH Study Out Of The Park
09:31am, Monday, 19'th Dec 2022
Madrigal scored a win in the particularly tricky NASH field on Monday after its study hit both its goals, sending MDGL stock flying. The post Madrigal Pharma Stock Triples After Knocking NASH Study Ou
Viking Therapeutics' stock rallies after Madrigal shares positive data about its liver drug
08:42am, Monday, 19'th Dec 2022
Shares of Viking Therapeutics Inc. VKTX, +4.42% jumped 55% in premarket trading on Monday after a company that is also developing a selective thyroid hormone receptor beta agonist as a treatment for n
Madrigal's stock rallies about 200% after sharing positive data about its NASH treatment candidate
08:07am, Monday, 19'th Dec 2022
Shares of Madrigal Pharmaceuticals Inc. MDGL, +1.43% soared 209.6% in premarket trading on Monday after the company shared positive data from a pivotal Phase 3 clinical trial assessing its experimenta
Tesla, Amazon, Madrigal Pharma, Pfizer, Synaptogenix: Why These 5 Stocks Are Drawing Investors' Attention Today
12:56am, Monday, 19'th Dec 2022 Benzinga
Major Wall Street indices had closed in the red on Friday in the wake of a continued sell-off following the hawkish stance asserted by the Federal Reserve. Friday witnessed volatile trading as a large
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
09:00pm, Sunday, 18'th Dec 2022 GlobeNewswire Inc.
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepa
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
04:00pm, Sunday, 18'th Dec 2022
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati
Madrigal: Binary Catalyst Unlocking
07:18am, Tuesday, 13'th Dec 2022
The recent Phase 3 (MAESTRO-NAFLD-1) study delivered extremely strong results. This month, Madrigal is expected to release the data for its Phase 3 (MAESTRO-NASH) trial.
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
10:00pm, Sunday, 06'th Nov 2022 The Motley Fool
These two healthcare stocks could deliver market-crushing gains by year's end.
2 Healthcare Stocks Poised to Rocket Higher in the 4th Quarter
05:00pm, Sunday, 06'th Nov 2022
These two healthcare stocks could deliver market-crushing gains by year's end.
Madrigal Pharmaceuticals Forecast: Not So Clear
09:28am, Saturday, 29'th Oct 2022
The biopsy readout for the pivotal MAESTRO-NASH study on lead product candidate resmetirom is slated for Q4. Many expect a successful trial based on positive Phase 2 data.
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
03:38pm, Thursday, 15'th Sep 2022 The Motley Fool
NASH is a common disease, but there are no approved treatments for it. These two drug companies have promising candidates in clinical trials.
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
11:38am, Thursday, 15'th Sep 2022
NASH is a common disease, but there are no approved treatments for it. These two drug companies have promising candidates in clinical trials.
